Protein composition of microparticles shed from human placenta during placental perfusion: Potential role in angiogenesis and fibrinolysis in preeclampsia

Placenta

Volumn 32, Issue 1, 2011, Pages 63-69

  Guller, S ^a   Tang, Z ^a   Ma, Y Y ^a   Di Santo, S ^b   Sager, R ^b   Schneider, H ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Dual perfusion; Endoglin; Flt 1; Placental microparticles; Plasminogen activators; Preeclampsia

Indexed keywords

ALKALINE PHOSPHATASE; ENDOGLIN; LIPOCORTIN 5; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ARTICLE; CELL MEMBRANE; CENTRIFUGATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MEMBRANE MICROPARTICLE; PLACENTA; PLACENTA DISORDER; PLACENTA PERFUSION; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SUPERNATANT;

EID: 78650516928     PISSN: 01434004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.placenta.2010.10.011     Document Type: Article

References (40)

1. A.S. Aly, M. Khandelwal, J. Zhao, A.H. Mehmet, M.D. Sammel, and S. Parry Neutrophils are stimulated by syncytiotrophoblast microvillous membranes to generate superoxide radicals in women with preeclampsia Am J Obstet Gynecol 190 2004 252 258
2. D. Goswami, D.S. Tannetta, L.A. Magee, A. Fuchisawa, C.W. Redman, and I.L. Sargent Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction Placenta 27 2006 56 61
3. A.K. Gupta, C. Rusterholz, B. Huppertz, A. Malek, H. Schneider, and W. Holzgreve A comparative study of the effect of three different syncytiotrophoblast micro-particles preparations on endothelial cells Placenta 26 2005 59 66
4. M. Knight, C.W. Redman, E.A. Linton, and I.L. Sargent Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies Br J Obstet Gynaecol 105 1998 632 640
5. B. Huppertz, H.G. Frank, J.C. Kingdom, F. Reister, and P. Kaufmann Villous cytotrophoblast regulation of the syncytial apoptotic cascade in the human placenta Histochem Cell Biol 110 1998 495 508
6. C.W. Redman, and I.L. Sargent Circulating microparticles in normal pregnancy and pre-eclampsia Placenta 29 Suppl. A 2008 S73 S77
7. A.K. Gupta, P. Hasler, W. Holzgreve, S. Gebhardt, and S. Hahn Induction of neutrophil extracellular DNA lattices by placental microparticles and IL-8 and their presence in preeclampsia Hum Immunol 66 2005 1146 1154
8. M. Messerli, K. May, S.R. Hansson, H. Schneider, W. Holzgreve, and S. Hahn Feto-maternal interactions in pregnancies: placental microparticles activate peripheral blood monocytes Placenta 31 2010 106 112
9. C.W. Redman, and I.L. Sargent Latest advances in understanding preeclampsia Science 308 2005 1592 1594
10. Z. Kertesz, G. Hurst, M. Ward, A.C. Willis, H. Caro, and E.A. Linton Purification and characterization of a complex from placental syncytiotrophoblast microvillous membranes which inhibits the proliferation of human umbilical vein endothelial cells Placenta 20 1999 71 79
11. D.E. Clark, S.K. Smith, Y. He, K.A. Day, D.R. Licence, and A.N. Corps A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation Biol Reprod 59 1998 1540 1548
12. Y. Gu, D.F. Lewis, and Y. Wang Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies J Clin Endocrinol Metab 93 2008 260 266
13. R.J. Levine, C. Lam, C. Qian, K.F. Yu, S.E. Maynard, and B.P. Sachs Soluble endoglin and other circulating antiangiogenic factors in preeclampsia N Engl J Med 355 2006 992 1005
14. R.J. Levine, S.E. Maynard, C. Qian, K.H. Lim, L.J. England, and K.F. Yu Circulating angiogenic factors and the risk of preeclampsia N Engl J Med 350 2004 672 683
15. S.E. Maynard, J.Y. Min, J. Merchan, K.H. Lim, J. Li, and S. Mondal Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia J Clin Invest 111 2003 649 658
16. T. Nagamatsu, T. Fujii, M. Kusumi, L. Zou, T. Yamashita, and Y. Osuga Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia Endocrinology 145 2004 4838 4845
17. Y. Yinon, O. Nevo, J. Xu, A. Many, A. Rolfo, and T. Todros Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-beta 3 Am J Pathol 172 2008 77 85
18. L.C. Chappell, P.T. Seed, A. Briley, F.J. Kelly, B.J. Hunt, and D.S. Charnock-Jones A longitudinal study of biochemical variables in women at risk of preeclampsia Am J Obstet Gynecol 187 2002 127 136
19. J.D. Vassalli, A.P. Sappino, and D. Belin The plasminogen activator/plasmin system J Clin Invest 88 1991 1067 1072
20. A. Estelles, J. Gilabert, M. Keeton, Y. Eguchi, J. Aznar, and S. Grancha Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation Blood 84 1994 143 150
21. R.K.W.P. Miller, Y. Shah, P.A. di Sant'Agnese, and R.P. D'Gregorio Criteria for in vitro dual perfusions in the human placental lobule: perfusions in excess of 12 hours New York Placenta as a model and a source 1989
22. H. Schneider The role of the placenta in nutrition of the human fetus Am J Obstet Gynecol 164 1991 967 973
23. S. Di Santo, R. Sager, A.C. Andres, S. Guller, and H. Schneider Dual in vitro perfusion of an isolated cotyledon as a model to study the implication of changes in the third trimester placenta on preeclampsia Placenta 28 Suppl. A 2007 S23 S32
24. S. Guller, Y. Ma, A. Malek, S. Di Santo, and H. Schneider Differential release of plasminogen activator inhibitors (PAIs) during dual perfusion of human placenta: implications in preeclampsia Placenta 28 2007 278 285
25. L. Myatt, and X. Cui Oxidative stress in the placenta Histochem Cell Biol 122 2004 369 382
26. S. Guller, C.S. Buhimschi, Y.Y. Ma, S.T. Huang, L. Yang, and E. Kuczynski Placental expression of ceruloplasmin in pregnancies complicated by severe preeclampsia Lab Invest 88 2008 1057 1067
27. S. Venkatesha, M. Toporsian, C. Lam, J. Hanai, T. Mammoto, and Y.M. Kim Soluble endoglin contributes to the pathogenesis of preeclampsia Nat Med 12 2006 642 649 (Pubitemid 43865232)
28. J.H. Distler, L.C. Huber, S. Gay, O. Distler, and D.S. Pisetsky Microparticles as mediators of cellular cross-talk in inflammatory disease Autoimmunity 39 2006 683 690
29. J.M. Roberts Preeclampsia: what we know and what we do not know Semin Perinatol 24 2000 24 28
30. A.P. Cockell, J.G. Learmont, A.K. Smarason, C.W. Redman, I.L. Sargent, and L. Poston Human placental syncytiotrophoblast microvillous membranes impair maternal vascular endothelial function Br J Obstet Gynaecol 104 1997 235 240
31. K.P. Radtke, K.H. Wenz, and N. Heimburger Isolation of plasminogen activator inhibitor-2 (PAI-2) from human placenta. Evidence for vitronectin/PAI-2 complexes in human placenta extract Biol Chem Hoppe-Seyler 371 1990 1119 1127
32. G. Krikun, C.J. Lockwood, X.X. Wu, X.D. Zhou, S. Guller, and C. Calandri The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation Placenta 15 1994 601 612
33. S. St-Jacques, M. Forte, S.J. Lye, and M. Letarte Localization of endoglin, a transforming growth factor-beta binding protein, and of CD44 and integrins in placenta during the first trimester of pregnancy Biol Reprod 51 1994 405 413
34. R.F. Feinberg, L.C. Kao, J.E. Haimowitz, J.T. Queenan Jr., T.C. Wun, and J.F. Strauss 3rd Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. PAI-1 is an immunocytochemical marker of invading trophoblasts Lab Invest 61 1989 20 26
35. Y. Li, S.M. Rizvi, M. Ranson, and B.J. Allen 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model Br J Cancer 86 2002 1197 1203
36. J. Reinartz, B. Schaefer, M.J. Bechtel, and M.D. Kramer Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator Exp Cell Res 223 1996 91 101
37. C.M. Salafia, V.K. Minior, J.C. Pezzullo, E.J. Popek, T.S. Rosenkrantz, and A.M. Vintzileos Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: associated placental pathologic features Am J Obstet Gynecol 173 1995 1049 1057
38. J.L. Dickinson, E.J. Bates, A. Ferrante, and T.M. Antalis Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function J Biol Chem 270 1995 27894 27904
39. C.A. Lok, A.N. Boing, I.L. Sargent, S.R. Sooranna, J.A. van der Post, and R. Nieuwland Circulating platelet-derived and placenta-derived microparticles expose Flt-1 in preeclampsia Reprod Sci 15 2008 1002 1010
40. M.J. VanWijk, R. Nieuwland, K. Boer, J.A. van der Post, E. VanBavel, and A. Sturk Microparticle subpopulations are increased in preeclampsia: possible involvement in vascular dysfunction? Am J Obstet Gynecol 187 2002 450 456